A review on nutraceuticals: A healthy way to treat brain cancer
Keywords:
Glioblastoma, Sulforaphane, Curcumin, Nutraceuticals, Brain cancerAbstract
A Balanced body is important for good health and for balancing the state of body, healthy food is necessary. Cancer is the uncontrolled growth of cells which upon time worsen and turns into tumor and as it is a leading cause of death worldwide, it is so important to research and find alternative treatments for the management of cancer. Nutraceuticals are known as alternative approach for the control of cancer. Nutraceuticals has many health benefits, and now known as the future of treatment for various health diseases. It has shown to elicit anti-aging, anti-cancer and other health enhancing effects. Nutraceuticals also have significant promise in the promotion of human health and disease prevention. Since, the present cancer treatment has various side effects, the benefits of these nutraceuticals may result in approaches to improve human health in a alternate way. In this review, we highlighted the etiology, diagnosis, pathogenesis of brain cancer along with treatment by using nutraceuticals.
Metrics
References
Shah V, Kochar P. Brain cancer: implication to disease, therapeutic strategies and tumor targeted drug delivery approaches. Recent patents on anti-cancer drug discovery. 1 Feb 2018; 13 (1): 70-85.
Mazur J, Roy K, Kanwar JR. Recent advances in nanomedicine and survivin targeting in brain cancers. Nanomedicine. Jan 2018; 13 (1): 105-37.
Sowers JL, Johnson KM, Conrad C, Patterson JT, Sowers LC. The role of inflammation in brain cancer. Inflammation and Cancer. 2014; 75-105.
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncology. 1 Jul 2014; 16 (7): 896-913.
Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacology & therapeutics. 1 Apr 2003; 98 (1): 71-108.
Wu SY, Watabe K. The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. Frontiers in bioscience (Landmark edition). 1 Jun 2017; 22: 18
Xiao H, Ding N, Liao H, Yao Z, Cheng X, Zhang J, Zhao M. Prediction of relapse and prognosis by expression levels of long noncoding RNA PEG10 in glioma patients. Medicine. Nov 2019; 98 (45).
What You Need To Know About Brain Tumors. U.S. Department of health and human services. National Cancer Institute. 2009; 1-46.
Mayfield Brain & Spine website. Available at www.mayfieldclinic.com/PE-BrainTumor.html (Accessed on: April 16, 2017
Friedman H, Liau, L. Brain Tumor Guide for the Newly Diagnosed. Musella Foundation for Brain Tumor Research & Information, Inc. 2012; 4-74.
Santini A, Novellino E. Nutraceuticals in hypercholesterolaemia: an overview. British journal of pharmacology. 1 Jun 2017; 174 (11): 1450-63.
Lin JK, Weng MS. Flavonoids as nutraceuticals. In The science of flavonoids. Springer, New York, NY. 2006; (213-238).
Vranešić-Bender D. The role of nutraceuticals in anti-aging medicine. Acta clinica Croatica. 20 Dec 2010; 49 (4): 537-44.
Sohail M, Rakha A, Butt MS, Iqbal MJ, Rashid S. Rice bran nutraceutics: A comprehensive review. Critical Reviews in Food Science and Nutrition. 22 Nov 2017; 57 (17): 3771-80.
Jain S, Buttar HS, Chintameneni M, Kaur G. Prevention of cardiovascular diseases with anti-inflammatory and anti-oxidant nutraceuticals and herbal products: an overview of pre-clinical and clinical studies. Recent patents on inflammation & allergy drug discovery. 1 Oct 2018; 12 (2): 145-57.
McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM, Cocco L, Ratti S. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY). Jun 2017; 9 (6): 1477.
Wargovich MJ, Morris J, Brown V, Ellis J, Logothetis B, Weber R. Nutraceutical use in late-stage cancer. Cancer and Metastasis Reviews. Sep 2010; 29 (3): 503-10.
De Mejia EG, Dia VP. The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells. Cancer and Metastasis Reviews. Sep 2010; 29 (3): 511-28.
Mandel S, Packer L, Youdim MB, Weinreb O. Proceedings from the “Third International Conference on mechanism of Action of Nutraceuticals”. The Journal of nutritional biochemistry. 1 Sep 2005; 16 (9): 513-20.
Shehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors. Jan 2013; 39 (1): 56-68.
Saldanha SN, Tollefsbol TO. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. Journal of oncology. 1 Jan 2012.
Calvani M, Pasha A, Favre C. Nutraceutical boom in cancer: Inside the labyrinth of reactive oxygen species. International journal of molecular sciences. Jan 2020; 21 (6): 1936.
Mantzorou M, Pavlidou E, Vasios G, Tsagalioti E, Giaginis C. Effects of curcumin consumption on human chronic diseases: A narrative review of the most recent clinical data. Phytotherapy Research. Jun 2018; 32 (6): 957-75.
Bondy ML, Scheurer ME, Malmer B, Barnholtz‐Sloan JS, Davis FG, Il'Yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, Sadetzki S. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 1 Oct 2008; 113 (S7): 1953-68.
Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep. May 2007; 7 (3): 208-14.
Ostrom QT, Barnholtz-Sloan JS. Current state of our knowledge on brain tumor epidemiology. Current neurology and neuroscience reports. 1 Jun 2011; 11 (3): 329-35.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama. 6 Nov 2013; 310 (17): 1842-50.
Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. Journal of neurosurgery. 1 Jun 1987; 66 (6): 865-74.
Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN. Diagnostic yield in CT-guided stereotactic biopsy of gliomas. Journal of neurosurgery. 1 Oct 1989; 71 (4): 494-7.
Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of mela-noma brain metastasis: a literature review. Cancer Control. Jul 2009; 16 (3): 248-55.
Shahpar S, Mhatre PV, Huang ME. Update on brain tumors: new developments in neuro-oncologic diagnosis and treatment, and impact on rehabilitation strategies. PM&R. 1 Jul 2016; 8 (7): 678-89.
Sita G, Hrelia P, Graziosi A, Morroni F. Sulforaphane from cruciferous vegetables: Recent advances to improve glioblastoma treatment. Nutrients. Nov 2018; 10 (11): 1755.
McNeill KA. Epidemiology of brain tumors. Neurologic clinics. 1 Nov 2016; 34 (4): 981-98.
Millard NE, De Braganca KC. Medulloblastoma. J Child Neurol. Oct 2016; 31 (12): 1341-53.
Sen A, Das C, Mukhopadhyay M, Mukhopadhyay S, Deb S, Mukhopadhyay B. Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67. Journal of postgraduate medicine. Apr 2017; 63 (2): 96.
Sarma S, Sekhar LN, Schessel DA. Nonvestibular schwannomas of the brain: a 7-year experience. Neurosurgery. 1 Mar 2002; 50 (3): 437-49.
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. Oct 2014; 16 (4): 1-63.
Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica. Jun 2016; 131 (6): 803-20.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The WHO classification of Tumors of the central nervous. 2007.
Stoyanov GS, Dzhenkov DL, Kitanova M, Ghenev P, Tonchev AB. Demographics and incidence of histologically confirmed intracranial tumors: a five-year, two-center prospective study. Cureus. 2017 Jul; 9 (7).system. Acta neuropathologica. 1 Aug 2007; 114 (2): 97-109.
Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y, Tonchev AB. Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. Medical Oncology. Mar 2018; 35 (3): 1-0.
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica. Jan 2005; 109 (1): 93-108.
Wirsching HG, Roth P, Weller M. A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion on Therapeutic Targets. 1 Feb 2021; 25 (2): 87-100.
Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, Hamada J. Aberrant signaling pathways in glioma. Cancers (Basel). 10 Aug 2011; 3 (3): 3242-78.
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncology. 1 Nov 2012; 14 (5): 1-49.
Stoyanov GS, Dzhenkov DL. On the concepts and history of glioblastoma multiforme-morphology, genetics and epigenetics. Folia medica. 1 Mar 2018; 60 (1): 48-66.
Schlegel J, Scherthan H, Arens N, Stumm G, Cremer T, Kiessling M. Detection of amplified DNA sequences by comparative genomic in situ hybridization with human glioma tumor DNA as probe. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1 Jan 1994; 78: 204-7.
Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. Journal of neuro-oncology. Oct 2000; 50 (1): 121-37.
Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI. A network model of a cooperative genetic landscape in brain tumors. Jama. 15 Jul 2009; 302 (3): 261-75.
Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. Jama. 15 Jul 2009; 302 (3): 276-89.
Lu Z, Hunter T. Prolyl isomerase Pin1 in cancer. Cell research. Sep 2014; 24 (9): 1033-49.
La Montagna R, Caligiuri I, Giordano A, Rizzolio F. Pin1 and nuclear receptors: a new language?. Journal of cellular physiology. Sep 2013; 228 (9): 1799-801.
Atkinson GP, Nozell SE, Harrison DK, Stonecypher MS, Chen D, Benveniste EN. The prolyl isomerase Pin1 regulates the NF-κB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene. Oct 2009; 28 (42): 3735-45.
Yang Y, Niu CS, Cheng CD. Pin1-Nanog expression in human glioma is correlated with advanced tumor progression. Oncology reports. 1 Aug 2013; 30 (2): 560-6.
Wang J, Liu K, Wang XF, Sun DJ. Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis. Oncology reports. 1 Oct 2017; 38 (4): 1959-66.
Nelson SJ, Cha S. Imaging glioblastoma multiforme. The Cancer Journal. 2003 Mar 1; 9 (2): 134-45.
Inda MD, Bonavia R, Seoane J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers. Mar 2014; 6 (1): 226-39.
Perus LJ, Walsh LA. Microenvironmental heterogeneity in brain malignancies. Frontiers in immunology. 1 Oct 2019; 10: 2294.
Klinger NV, Mittal S. Therapeutic potential of curcumin for the treatment of brain tumors. Oxidative medicine and cellular longevity. 1 Jan 2016; 2016.
Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, Chan SY, Dai X, Ye J, Ho PC, Duan W. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. International immunopharmacology. 1 Mar 2006; 6 (3): 499-508.
Campos-Bedolla P, Walter FR, Veszelka S, Deli MA. Role of the blood–brain barrier in the nutrition of the central nervous system. Archives of medical research. 1 Nov 2014; 45 (8): 610-38.
He Y, Yue Y, Zheng X, Zhang K, Chen S, Du Z. Curcumin, inflammation, and chronic diseases: how are they linked?. Molecules. May 2015; 20 (5): 9183-213.
DiDonato JA, Mercurio F, Karin M. NF‐κB and the link between inflammation and cancer. Immunological reviews. Mar 2012; 246 (1): 379-400.
Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, Zhang X. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. Journal of neuro-oncology. Dec 2007; 85 (3): 263-70.
Deborah F, Sofia MM, Romina B, Claudia M, Guido F, Gregorio C, Antonella S, Francesco C, Antonio S. Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells. Phytomedicine. 2018.
Elamin MH, Shinwari Z, Hendrayani SF, Al‐Hindi H, Al‐Shail E, Khafaga Y, Al‐kofide A, Aboussekhra A. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Molecular Carcinogenesis: Published in cooperation with the University of Texas MD Anderson Cancer Center. Mar 2010; 49 (3): 302-14.
Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Critical reviews in food science and nutrition. 2 Sep 2017; 57 (13): 2889-95.
Guo YQ, Cao JS, Zhang L. Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation. Cell Physiol Biochem. 2015; 35: 1381-93.
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Advances in Nutrition. Jul 2014; 5 (4): 404-17.
Chanet A, Milenkovic D, Manach C, Mazur A, Morand C. Citrus flavanones: what is their role in cardiovascular protection?. Journal of agricultural and food chemistry. 12 Sep 2012; 60 (36): 8809-22.
Li H, Yang B, Huang J, Xiang T, Yin X, Wan J, Luo F, Zhang L, Li H, Ren G. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway. Toxicology letters. 18 Jul 2013; 220 (3): 219-28.
Esmaeili MA, Alilou M. Naringenin attenuates CC l4‐induced hepatic inflammation by the activation of an Nrf2‐mediated pathway in rats. Clinical and Experimental Pharmacology and Physiology. Jun 2014; 41 (6): 416-22.
Kanno SI, Shouji A, Tomizawa A, Hiura T, Osanai Y, Ujibe M, Obara Y, Nakahata N, Ishikawa M. Inhibitory effect of naringin on lipopolysaccharide (LPS)-induced endotoxin shock in mice and nitric oxide production in RAW 264.7 macrophages. Life Sciences. 11 Jan 2006; 78 (7): 673-81.
Bharti S, Rani N, Krishnamurthy B, Arya DS. Preclinical evidence for the pharmacological actions of naringin: a review. Planta medica. 1 Apr 2014; 80 (06): 437-51.
Li S, Hua ZC. FAK expression: regulation and therapeutic potential. Advances in cancer research. 1 Jan 2008; 101: 45-61.
Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM. Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. Journal of Biological Chemistry. 25 May 2012; 287 (22): 18656-73.
Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer research. 15 Jan 2009; 69 (2): 466-74.
Peng X, Ueda H, Zhou H, Stokol T, Shen TL, Alcaraz A, Nagy T, Vassalli JD, Guan JL. Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovascular research. 1 Dec 2004; 64 (3): 421-30.
Serrels A, Canel M, Brunton VG, Frame MC. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell adhesion & migration. 1 Jul 2011; 5 (4): 360-5.
Huang G, Ho B, Conroy J, Liu S, Qiang H, Golubovskaya V. The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 1 Jan 2014; 14 (1): 9-17.
Li J, Dong Y, Hao G, Wang B, Wang J, Liang Y, Liu Y, Zhen E, Feng D, Liang G. Naringin suppresses the development of glioblastoma by inhibiting FAK activity. Journal of drug targeting. 2 Jan 2017; 25 (1): 41-8.
Aroui S, Najlaoui F, Chtourou Y, Meunier AC, Laajimi A, Kenani A, Fetoui H. Naringin inhibits the invasion and migration of human glioblastoma cell via downregulation of MMP-2 and MMP-9 expression and inactivation of p38 signaling pathway. Tumor Biology. 1 Mar 2016; 37 (3): 3831-9.
Yan X, Zhang G, Bie F, Lv Y, Ma Y, Ma M, Wang Y, Hao X, Yuan N, Jiang X. Eugenol inhibits oxidative phosphorylation and fatty acid oxidation via downregulation of c-Myc/PGC-1β/ERRα signaling pathway in MCF10A-ras cells. Scientific reports. 10 Oct 2017; 7 (1): 1-3.
Fujisawa S, Murakami Y. Eugenol and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016; 929: 45-66.
Liang WZ, Chou CT, Hsu SS, Liao WC, Shieh P, Kuo DH, Tseng HW, Kuo CC, Jan CR. The involvement of mitochondrial apoptotic pathway in eugenol-induced cell death in human glioblastoma cells. Toxicology letters. 5 Jan 2015; 232 (1): 122-32.
Wohlmuth H, Leach DN, Smith MK, Myers SP. Gingerol content of diploid and tetraploid clones of ginger (Zingiber officinale Roscoe). Journal of agricultural and food chemistry. 2005 Jul 13; 53 (14): 5772-8.
Semwal RB, Semwal DK, Combrinck S, Viljoen AM. Gingerols and shogaols: Important nutraceutical principles from ginger. Phytochemistry. 1 Sep 2015; 117: 554-68.
Joo JH, Hong SS, Cho YR, Seo DW. 10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38MAPK activity. Oncology reports. 1 Feb 2016; 35 (2): 779-84.
Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer and Metastasis Reviews. Dec 2018; 37 (4): 733-48.
Lee DH, Kim DW, Jung CH, Lee YJ, Park D. Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells. Toxicology and applied pharmacology. 15 Sep 2014; 279 (3): 253-65.
Ahmad T, Khan T, Alamgeer, Shah AJ. Juglone as antihypertensive agent acts through multiple vascular mechanisms. Clinical and Experimental Hypertension. 18 May 2020; 42 (4): 335-44.
Wu J, Zhang H, Xu Y, Zhang J, Zhu W, Zhang Y, Chen L, Hua W, Mao Y. Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma. BMC neurology. Dec 2017; 17 (1): 1-7.
El-Bakoush A, Olajide OA. Formononetin inhibits neuroinflammation and increases estrogen receptor beta (ERβ) protein expression in BV2 microglia. International immunopharmacology. 1 Aug 2018; 61: 325-37.
Park S, Bazer FW, Lim W, Song G. The O‐methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation. Journal of cellular biochemistry. Sep 2018; 119 (9): 7377-87.
Wu D, Wu K, Zhu Q, Xiao W, Shan Q, Yan Z, Wu J, Deng B, Xue Y, Gong W, Lu G. Formononetin administration ameliorates dextran sulfate sodium-induced acute colitis by inhibiting NLRP3 inflammasome signaling pathway. Mediators of inflammation. 8 Jan 2018.
Chin YW, Jung HA, Liu Y, Su BN, Castoro JA, Keller WJ, Pereira MA, Kinghorn AD. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). Journal of agricultural and food chemistry. 13 Jun 2007; 55 (12): 4691-7.
Jiang D, Rasul A, Batool R, Sarfraz I, Hussain G, Mateen Tahir M, Qin T, Selamoglu Z, Ali M, Li J, Li X. Potential anticancer properties and mechanisms of action of formononetin. BioMed research international. 28 Jul 2019; 2019.
Zhang X, Ni Q, Wang Y, Fan HW, Li Y. Synergistic anticancer effects of formononetin and temozolomide on glioma C6 cells. Biological and Pharmaceutical Bulletin. 2018; b18-00002.
Tan JW, Tham CL, Israf DA, Lee SH, Kim MK. Neuroprotective effects of biochanin A against glutamate-induced cytotoxicity in PC12 cells via apoptosis inhibition. Neurochemical research. Mar 2013; 38 (3): 512-8.
Gupta RK, Gupta K, Sharma A, Das M, Ansari IA, Dwivedi PD. Health risks and benefits of chickpea (Cicer arietinum) consumption. Journal of agricultural and food chemistry. 11 Jan 2017; 65 (1): 6-22.
Chen HQ, Jin ZY, Li GH. Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation. Neuroscience letters. 1 May 2007; 417 (2): 112-7.
Desai V, Jain A, Shaghaghi H, Summer R, Lai JC, Bhushan A. Combination of biochanin A and temozolomide impairs tumor growth by modulating cell metabolism in glioblastoma multiforme. Anticancer research. 1 Jan 2019; 39 (1): 57-66.
Raffoul JJ, Heydari AR, Hillman GG. DNA repair and cancer therapy: targeting APE1/Ref-1 using dietary agents. Journal of oncology. 1 Jan 2012.
Yu C, Zhang P, Lou L, Wang Y. Perspectives regarding the role of biochanin A in humans. Frontiers in pharmacology. 12 Jul 2019; 10: 793.
Puli S, Lai JC, Bhushan A. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. Journal of Neuro-oncology. Sep 2006; 79 (2): 135-42.
Carlos-Reyes Á, López-González JS, Meneses-Flores M, Gallardo-Rincón D, Ruíz-García E, Marchat LA, Astudillo-De La Vega H, Hernández de la Cruz ON, López-Camarillo C. Dietary compounds as epigenetic modulating agents in cancer. Frontiers in genetics. 1 Mar 2019; 10: 79.
Vidak M, Rozman D, Komel R. Effects of flavonoids from food and dietary supplements on glial and glioblastoma multiforme cells. Molecules. Oct 2015; 20 (10): 19406-32.
Liu Y, Tang ZG, Lin Y, Qu XG, Lv W, Wang GB, Li CL. Effects of quercetin on proliferation and migration of human glioblastoma U251 cells. Biomedicine & pharmacotherapy. 1 Aug 2017; 92: 33-8.
Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. Nov 1990; 348 (6299): 334-6.
Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules. Nov 2010; 15 (11): 7792-814.
Clark PA, Bhattacharya S, Elmayan A, Darjatmoko SR, Thuro BA, Yan MB, van Ginkel PR, Polans AS, Kuo JS. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. Journal of neurosurgery. 1 May 2017; 126 (5): 1448-60.
Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One. 2011; 6 (6): e20849.
Calvaruso M, Pucci G, Musso R, Bravatà V, Cammarata FP, Russo G, Forte GI, Minafra L. Nutraceutical compounds as sensitizers for cancer treatment in radiation therapy. International journal of molecular sciences. Jan 2019; 20 (21): 5267.
Yagishita Y, Fahey JW, Dinkova-Kostova AT, Kensler TW. Broccoli or sulforaphane: is it the source or dose that matters? Molecules. Jan 2019; 24 (19): 3593.
Tortorella SM, Royce SG, Licciardi PV, Karagiannis TC. Dietary sulforaphane in cancer chemoprevention: the role of epigenetic regulation and HDAC inhibition.
Antioxidants & redox signaling. 1 Jun 2015; 22 (16): 1382-424.
Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, Zhu J, Zhang YH, Chen YS, Friesen MD, Jacobson LP. Bioavailability of sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prevention Research. 1 Mar 2011; 4 (3): 384-95.
Zhang Z, Li C, Shang L, Zhang Y, Zou R, Zhan Y, Bi B. Sulforaphane induces apoptosis and inhibits invasion in U251MG glioblastoma cells. Springerplus. Dec 2016; 5 (1): 1-2.
Wu S, Zhou Y, Yang G, Tian H, Geng Y, Hu Y, Lin K, Wu W. Sulforaphane-cysteine induces apoptosis by sustained activation of ERK1/2 and caspase 3 in human glioblastoma U373MG and U87MG cells. Oncology reports. 1 May 2017; 37 (5): 2829-38.
Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. International journal of oncology. 31 Jan 2016; 48 (2): 559-68.
Karmakar S, Weinberg MS, Banik NL, Patel SJ, Ray SK. Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience. 1 Jan 2006; 141 (3): 1265-80.
Parney IF. Basic concepts in glioma immunology. Glioma. 2012; 42-52.
Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurgery Clinics. 1 Jan 2010; 21 (1): 31-42.
Kumar R, De Mooij T, Peterson TE, Kaptzan T, Johnson AJ, Daniels DJ, Parney IF. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. PloS one. 30 Jun 2017; 12 (6): e0179012.
Arcella A, Oliva MA, Sanchez M, Staffieri S, Esposito V, Giangaspero F, Cantore G. Effects of hispolon on glioblastoma cell growth. Environmental toxicology. Sep 2017; 32 (9): 2113-23.
Lu TL, Huang GJ, Lu TJ, Wu JB, Wu CH, Yang TC, Iizuka A, Chen YF. Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells. Food and chemical toxicology. 1 Aug 2009; 47 (8): 2013-21.
Chatterjee S, Sarma MK, Deb U, Steinhauser G, Walther C, Gupta DK. Mushrooms: from nutrition to mycoremediation. Environmental Science and PollutionResearch. Aug 2017; 24 (24): 19.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
